Da Ines D, Chabrot P, Cassagnes L, Merle P, Filaire M, Ravel A, Garcier JM, Boyer L. [Endovascular treatment of SVC syndrome from neoplastic origin: a review of 34 cases].
ACTA ACUST UNITED AC 2008;
89:881-90. [PMID:
18772750 DOI:
10.1016/s0221-0363(08)73876-9]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
PURPOSE
To report our experience with the treatment of 34 patients with SVC syndrome from neoplastic origin using the Wallstent.
MATERIALS AND METHODS
Thirty-four patients were treated between January 2000 and February 2007: 21 males and 13 females, aged 44-81 years, with non-small-cell lung carcinoma in 27 cases (79%), small-cell lung carcinoma in 5 cases (15%) and metastatic breast adenocarcinoma to the mediastinum in 2 cases (6%). All patients were treated using the stainless steel self-expanding Wallstent. A dual brachial-femoral access was used in all cases.
RESULTS
Stent placement was possible in all cases. Per procedure acute respiratory distress occurred in 2 cases: 1 case of acute pulmonary edema and 1 case of tamponade. Symptoms resolved within 24 hours. Twenty-six patients died from disease progression, 8 during the first month, and 16 within 32-545 days post-procedure (mean: 213.4 days). Five patients with recurrent SVC syndrome underwent repeat treatment (restenosis in 3 cases, fracture in 1 case, thrombosis in 1 case), for primary and secondary patency rates of 81% and 100%.
CONCLUSION
Palliative stent treatment of neoplastic SVC syndrome is reliable, safe and provides long-standing improvement in quality of life.
Collapse